Laidlaw downgraded Taiwan Liposome from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2021 | $11.00 → $7.50 | Buy → Neutral | H.C. Wainwright |
| 7/7/2021 | Buy → Hold | Laidlaw |
CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)
CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)
6-K - Taiwan Liposome Company, Ltd. (0001722890) (Filer)
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the agreement, signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for the development of the product and EVL will primarily be responsible fo
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months wit
This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Rule 802 thereof. No public offering of such securities will be made in the United States. Such transaction has not been and
H.C. Wainwright downgraded Taiwan Liposome from Buy to Neutral and set a new price target of $7.50 from $11.00 previously
Laidlaw downgraded Taiwan Liposome from Buy to Hold
SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)
SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)
SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)